- PDF Free Download

Size: px

Start display at page:

Download ""

Silas Thornton
5 years ago
Views:

1 INTERNATIONAL WORKSHOP ON MANAGEMENT OF END STAGE LIVER DISEASE DUE TO NASH WASHINGTON DC, USA 6-7 OCTOBER 2016 MEETING PROSPECTUS

3 INTRODUCTION NAFLD and NASH have become one of the most important causes of cirrhosis and liver failure and they are expected to become the leading cause for liver transplantation by Because individuals with NASH cirrhosis often have significant obesity and other metabolic co-morbidities, there is a big concern that many patients with decompensated cirrhosis due to NASH are considered either high risk or deemed ineligible for liver transplantation. There is an urgent need to optimize comorbidities including BMI prior to listing for liver transplantation. A sizable proportion of patients with NASH who undergo liver transplantation will have recurrence of their liver disease and are at risk for losing their allograft or dying of complications, such as cardiovascular disease. The risk factors, natural history or management of post-transplant NASH are poorly understood and additionally how best to manage comorbidities such as dyslipidemia, obesity and metabolic syndrome is unclear. The 1 ST INTERNATIONAL WORKSHOP ON MANAGEMENT OF END STAGE LIVER DISEASE IN NASH is developed in order to meet the urgent need for translation and education on this topic for healthcare professionals involved in daily management of NASH patients. The program will cover important topics such as transplant candidacy, post-transplant management, advanced NASH and monitoring advanced disease. International and national experts will present, discuss and translate the latest findings to daily clinical practice. Much time will be allocated for discussion, debate and Q&A in order to maximize interaction. We encourage you to contribute to this important program! Kind regards, The Steering Committee 3

4 CONTENT Introduction... 3 Workshop description... 5 Background... 5 Meeting Objectives... 5 Learning Objectives... 5 Format... 5 Program Topics... 5 Unique Meeting Features... 6 Target Audience... 6 Steering Committee... 7 Preliminary Program... 8 Summary and Contact Details

5 WORKSHOP DESCRIPTION BACKGROUND NAFLD and NASH have become one of the most important causes of cirrhosis and liver failure and they are expected to become the leading cause for liver transplantation by Because individuals with NASH cirrhosis often have significant obesity and other metabolic co-morbidities, there is a big concern that many patients with decompensated cirrhosis due to NASH are considered either high risk or deemed ineligible for liver transplantation. There is urgent need to optimize comorbidities including BMI prior to listing for liver transplantation. A sizable proportion of patients with NASH who undergo liver transplantation will have recurrence of their liver disease and are at risk for losing their allograft or dying of complications, such as cardiovascular disease. The risk factors, natural history or management of post-transplant NASH are poorly understood and additionally how best to manage comorbidities such as dyslipidemia, obesity and metabolic syndrome is unclear. MEETING OBJECTIVE The objective of this meeting is to create an interactive setting in which international and national experts will present, discuss and translate the latest findings on NASH and NAFLD to daily clinical practices. LEARNING OBJECTIVES To better understand the issues and controversies related to transplant candidacy in patients with decompensated cirrhosis due to nonalcoholic fatty liver disease To better understand therapeutic options available to reverse advanced NASH To better understand the pathogenesis, natural history and management of recurrent NASH and associated metabolic co-morbidities in liver transplant recipients FORMAT The workshop will be interactive with presentations and discussions bringing different stakeholders together. Depending on the program, the workshops will be 1 or 1,5 day. Much time will be allocated for discussion, debate and Q&A in order to maximize interaction. TOPIC AREAS The meeting will focus on clinical utility of biomarkers and non-invasive assessment of NASH/advanced liver disease/transplant population. Topics covered in the program are: determining transplant candidacy, unique aspects of post-transplant management, advanced NASH can it reverse?, and monitoring advanced disease and the liver allograft. 5

6 UNIQUE MEETING FEATURES The workshop is a unique educational platform for clinicians and other medical professionals involved in treating patients with NASH A high quality international platform focusing on translating the latest findings into daily clinical practice The program brings together healthcare professionals from different disciplines involved in the field of NASH encouraging cross-disciplinary discussions and approaches TARGET AUDIENCE This program focuses on physicians, fellows, residents, physician assistants, nurses/nurse practitioners, and pharmacists working in the field of hepatology, gastroenterology, diabetology, transplantation, internal medicine, and other disciplines involved in treatment of NASH. 6

STEERING COMMITTEE PIERRE BEDOSSA, MD, PhD

CUSI, MD, FACP, FACE University of Florida, USA

Netherlands GREG EVERSON MD, FACP University of

University of Missouri, USA PHILIP NEWSOME, PhD,

SANYAL, MD Virginia Commonwealth University, USA

7 STEERING COMMITTEE PIERRE BEDOSSA, MD, PhD University of Paris- Diderot, France KENNETH CUSI, MD, FACP, FACE University of Florida, USA ROB DE KNEGT Erasmus Medical Center, The Netherlands GREG EVERSON MD, FACP University of Colorado Denver, USA ELIZABETH PARKS, PhD University of Missouri, USA PHILIP NEWSOME, PhD, FRCPE University of Birmingham, UK ARUN J. SANYAL, MD Virginia Commonwealth University, USA 7 1st International Workshop Management of end Stage Liver Disease due to NASH

8 PRELIMINARY PROGRAM THURSDAY 6 OCTOBER 1.00 PM Lunch 2.00 PM Opening of the Workshop - Workshop Chairs Session 1: Determining Transplant Candidacy 2.15 PM Cardiovascular assessment Sam Lee, MD, University of Calgary, Calgary, Canada 2.45 PM Bariatric Surgery - converting a non-candidate to candidate Michael Charlton, MD, Intermountain Medical Center, Salt Lake City, USA 3.15 PM Debate: BMI Targets // what is an acceptable BMI Lee Kaplan, MD, PhD, Massachusetts General Hospital, Boston, USA Julie Heimbach, MD, Mayo Clinic Minnesota, Rochester, USA 4.00 PM Coffee Break Session 2: Monitoring disease severity and recurrence after liver transplant 4.30 PM Liver biopsy Mary Rinella, MD, Northwestern University Feinberg School of Medicine, Chicago, USA 4.45 PM Non invasive Approaches Greg Everson, MD, FACP, University of Colorado Denver, Denver, USA 5.00 PM Fibroscan Mohammed Siddiqui, MD, Virginia Commonwealth University, Richmond, USA 5.15 PM MRI Claude Sirlin, MD, University of California San Diego, San Diego, USA 5.30 PM Panel discussion (based on Clinical Cases) 6.00 PM End of DAY 1 & Workshop Dinner 8

9 PRELIMINARY PROGRAM FRIDAY 7 OCTOBER Session 3: Management of Advanced NASH - can it be reversed? 8.30 AM Lifestyle modifications Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD, Swedish Medical Center, Seattle, USA 8.45 AM Diabetes control Kenneth Cusi, MD, FACP, FACE, University of Florida, Gainesville, USA 9.00 AM Drug and medications Arun Sanyal, MD, MBBS, Virginia Commonwealth University, Richmond, USA 9.15 AM General discussion on the pitfalls (all panel members) AM Coffee Break Session 4: Unique aspects of post-transplant management AM Frequency of Post-LT metabolic syndrome Kiran Bambha, MD, University of Colorado Health Sciences Center, Denver, USA AM Optimizing immunosuppression to reduec metabolic syndrome Russel Wiesner, MD, Mayo Clinic Minnesota, Rochester, USA AM Diabetes and metabolic control after transplant for NASH Kittie Wynne, MD, PhD, Imperial College London, London, United Kingdom AM Optimizing cardiovascular outcomes after transplant for NASH Kathleen Corey, MD, MPH, Massachusetts General Hospital, Boston, USA PM Renal issues following transplant for NASH Pratima Sharma, MBBS, University of Michigan, Ann Arbor, USA PM Discussion 1.00 PM Closing of the Workshop 9

10 SUMMARY AND CONTACT DETAILS The Steering Committee is looking forward to organizing the 1 ST INTERNATIONAL WORKSHOP ON MANAGEMENT OF END STAGE LIVER DISEASE DUE TO NASH in 2016 to meet the urgent need for translation and education on this topic for healthcare professionals involved in daily management of NASH patients. We trust that this program will greatly contribute to enhancing the understanding of treatment options for NASH patients and hope the information in this meeting prospectus is of interest to you. Please contact us if you would like to receive further information on a specific topic. We look forward to working with you on this exciting program! On behalf of the Expert Medical Events team, Alice Posthumus-Plantinga Managing Director CONTACT DETAILS Expert Medical Events Biltstraat BJ Utrecht T: +31 (0) M: +31 (0) E: alice.posthumus-plantinga@expertmedicalevents.com 10

MEETING PROSPECTUS. International Workshop on NASH Biomarkers

MEETING PROSPECTUS. International Workshop on NASH Biomarkers International Workshop on NASH Biomarkers 2018 18-19 May 2018 Washington, D.C., USA MEETING PROSPECTUS www.expertmedicaleducation.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE